Jan. 9, 2012
/PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it successfully met its projection that it would have 25 trial sites open and recruiting by the end of Q4, 2011, in its ongoing clinical trial of DCVax
immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company likewise met or exceeded the projections it had set for the two preceding quarters (Q2 and Q3, 2011), as previously announced.
The Company plans to continue adding clinical trial sites, and expects to have at least 30 sites open and enrolling by the end of Q1, 2012. The Company will also continue pursuing its programs in Europe. The open and active trial sites are listed on the U.S. Government's website,
, and on NW Bio's website,
As previously stated, the Company's steady progress continues to reflect the growing interest from both physicians and patients, and a growing awareness of the positive data from the Company's prior clinical trials for GBM brain cancer. In those trials, patients who received DCVax
showed a median survival of 3 years compared with median survival of 14.6 months for patients who received standard of care (surgery, radiation and chemotherapy). Patients who received DCVax
also experienced a substantially longer time to tumor recurrence: a median of 2 years, compared with 6.9 months in patients who received standard of care. DCVax
was well-tolerated, with no toxic side effects.
, CEO of NW Bio, commented that, "It is exciting to see the strong and growing interest from an ever widening array of medical centers across the country. This is giving us a broad ability to reach GBM brain cancer patients throughout the country, and to provide multiple location choices for these patients."
About Northwest Biotherapeutics